Where Is J&J Investing For The Future? Cell Therapy, Gene Therapy And RNA
Executive Summary
Janssen global head of R&D Mathai Mammen said the three areas are therapeutic modalities J&J is prioritizing for future drug development, both internally and through partnering.
You may also be interested in...
Vir Advances HBV, Flu Programs While Focused On COVID-19
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.
In Vivo's Rough Guide On The State Of RNAi
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.
Scrip’s Rough Guide On The State Of RNAi
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.